8-K: Y-mAbs Reports Third Quarter 2024 Financial Results, DANYELZA Patent Extended

Y-mAbs Therapeutics announced its third quarter 2024 financial results, including a 10% revenue decrease, but highlighted a new licensing agreement in Japan and a patent extension for DANYELZA.

Summary

• Y-mAbs Therapeutics reported a net revenue of $18.5 million for the third quarter of 2024, a 10% decrease compared to the same period in 2023.
• The company's U.S. DANYELZA net product revenues decreased by 5% to $15.3 million, while ex-U.S. revenues declined by 19% to $3.1 million.
• Y-mAbs entered into an exclusive license and distribution agreement with Nobelpharma for DANYELZA in Japan, receiving an upfront payment of $2.0 million in the fourth quarter of 2024.
• The primary U.S. patent for DANYELZA was extended through February 2034.
• The company's net loss for the quarter was $7.0 million, an improvement from the $7.7 million loss in the same quarter of the previous year.
• Y-mAbs had $68.1 million in cash and cash equivalents as of September 30, 2024.
• The company reiterated its full-year 2024 guidance for total net revenues between $87 million and $95 million, operating expenses between $115 million and $120 million, and total annual cash investment between $15 million and $20 million.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative. While there are positives like the patent extension and the Japan licensing deal, the revenue decline and increased expenses are concerning. The company is also still reporting a net loss.

Positives

• Y-mAbs secured an exclusive license and distribution agreement with Nobelpharma for DANYELZA in Japan, which includes a $2.0 million upfront payment.
• The primary U.S. patent for DANYELZA was extended through February 2034, providing long-term market exclusivity.
• The company's net loss decreased compared to the same quarter last year, indicating improved financial performance.
• Y-mAbs is expanding its market reach with the launch of a named patient program in Turkey.
• The company's cash position remains strong at $68.1 million, supporting operations into 2027.
• Gross margins increased in the nine months ended September 30, 2024, due to a favorable gross profit mix from revenue in international regions.

Negatives

• Total net revenues decreased by 10% in the third quarter of 2024 compared to the same period in 2023.
• U.S. DANYELZA net product revenues decreased by 5% in the third quarter of 2024.
• Ex-U.S. DANYELZA net product revenues decreased by 19% in the third quarter of 2024.
• The company reported a net loss of $7.0 million for the quarter.
• Selling, general, and administrative expenses increased by $3.4 million in the third quarter of 2024, primarily due to separation and consulting agreements with the former CFO, personnel costs, and professional fees.
• The company's net loss for the nine months ended September 30, 2024, increased to $22.9 million, primarily due to legal settlements.

Risks

• The company's revenue is declining, particularly in the U.S. and ex-U.S. markets for DANYELZA.
• Increased selling, general, and administrative expenses are impacting profitability.
• The company is facing legal settlements that are increasing net losses.
• The company's reliance on third parties for clinical testing and product manufacturing poses a risk.
• The company's future success depends on the market acceptance of its products and the ability to obtain sufficient reimbursement.
• The company is exposed to macroeconomic risks, including inflation, increased interest rates, and global market disruptions.

Future Outlook

Management reiterates its full-year 2024 guidance, anticipating total net revenues between $87 million and $95 million, operating expenses between $115 million and $120 million, and total annual cash investment between $15 million and $20 million. The company expects cash and cash equivalents to support operations into 2027.

Management Comments

• Michael Rossi, President and Chief Executive Officer, stated that the third quarter was one of continued focus and execution across the DANYELZA commercial business and the SADA PRIT radiopharmaceutical platform development pipeline.
• Rossi noted that physician usage of DANYELZA in the U.S. remains very strong for patients with relapsed/refractory high-risk neuroblastoma.
• Rossi mentioned the company continues to drive ex-U.S. market expansion with the new exclusive license and distribution agreement with Nobelpharma in Japan and the launch of the named patient program in Turkey.

Industry Context

This announcement reflects the challenges faced by biopharmaceutical companies in commercializing novel therapies, particularly in the context of fluctuating sales and market dynamics. The licensing agreement with Nobelpharma is a positive step for expanding market reach, while the patent extension provides long-term security for DANYELZA. The company's focus on its SADA PRIT platform also aligns with the industry trend towards innovative cancer treatments.

Comparison to Industry Standards

• Y-mAbs' revenue decline in the third quarter contrasts with some other biopharmaceutical companies that have shown growth in similar periods, such as companies with successful product launches or expanded market penetration.
• The company's gross margin improvement is a positive sign, but it needs to be sustained and improved further to match industry leaders.
• The increase in selling, general, and administrative expenses is higher than some of its peers, indicating a need for better cost management.
• The company's cash position is relatively strong compared to some smaller biotech companies, but it needs to be managed carefully to support ongoing operations and development programs.
• The patent extension for DANYELZA is a significant advantage, providing a longer period of market exclusivity compared to companies with shorter patent protection.

Legal Proceedings

• The company incurred a net impact of $3.6 million related to the settlement of a shareholder class-action lawsuit in the nine months ended September 30, 2024.
• An additional legal settlement of $0.2 million was incurred in the nine months ended September 30, 2024.

Stakeholder Impact

• Shareholders may be concerned about the revenue decline and increased net loss.
• Employees may be affected by the company's restructuring and cost-cutting measures.
• Customers (physicians and patients) may benefit from the continued availability of DANYELZA and the development of new therapies.
• Suppliers and creditors may be impacted by the company's financial performance.

Next Steps

• The company will complete Part A of its GD2-SADA Phase 1 trial this year and present the data in the first quarter of next year.
• Y-mAbs plans to transition its headquarters to Princeton, New Jersey, in the first half of 2025.
• The company will continue to focus on the commercialization of DANYELZA and the development of its SADA PRIT platform.

Key Dates

Keywords

DANYELZA, Y-mAbs, Neuroblastoma, SADA PRIT, Radioimmunotherapy, Financial Results, Patent Extension, Nobelpharma, License Agreement, Net Revenue